nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—HPGDS—urinary bladder cancer	0.448	1	CbGaD
Dinoprostone—ABCC5—Fluorouracil—urinary bladder cancer	0.0575	0.161	CbGbCtD
Dinoprostone—SLCO3A1—Methotrexate—urinary bladder cancer	0.0496	0.139	CbGbCtD
Dinoprostone—ABCC5—Cisplatin—urinary bladder cancer	0.0488	0.137	CbGbCtD
Dinoprostone—SLCO1C1—Methotrexate—urinary bladder cancer	0.0317	0.089	CbGbCtD
Dinoprostone—SLC22A7—Fluorouracil—urinary bladder cancer	0.0283	0.0793	CbGbCtD
Dinoprostone—ABCC4—Fluorouracil—urinary bladder cancer	0.0276	0.0775	CbGbCtD
Dinoprostone—SLC22A2—Cisplatin—urinary bladder cancer	0.0171	0.048	CbGbCtD
Dinoprostone—SLC22A11—Methotrexate—urinary bladder cancer	0.0164	0.0459	CbGbCtD
Dinoprostone—SLC22A7—Methotrexate—urinary bladder cancer	0.0156	0.0438	CbGbCtD
Dinoprostone—ABCC4—Methotrexate—urinary bladder cancer	0.0152	0.0428	CbGbCtD
Dinoprostone—SLCO1A2—Methotrexate—urinary bladder cancer	0.0109	0.0307	CbGbCtD
Dinoprostone—SLCO1B1—Methotrexate—urinary bladder cancer	0.0103	0.0289	CbGbCtD
Dinoprostone—SLC22A8—Methotrexate—urinary bladder cancer	0.00952	0.0267	CbGbCtD
Dinoprostone—SLC22A6—Methotrexate—urinary bladder cancer	0.00663	0.0186	CbGbCtD
Dinoprostone—CYP1A2—Fluorouracil—urinary bladder cancer	0.00613	0.0172	CbGbCtD
Dinoprostone—CYP1A2—Etoposide—urinary bladder cancer	0.00511	0.0143	CbGbCtD
Dinoprostone—HPGDS—urine—urinary bladder cancer	0.00351	0.0496	CbGeAlD
Dinoprostone—SLC51B—prostate gland—urinary bladder cancer	0.00236	0.0334	CbGeAlD
Dinoprostone—PTGER2—prostate gland—urinary bladder cancer	0.00175	0.0248	CbGeAlD
Dinoprostone—PTGER4—prostate gland—urinary bladder cancer	0.00172	0.0243	CbGeAlD
Dinoprostone—SLC51A—prostate gland—urinary bladder cancer	0.00169	0.0239	CbGeAlD
Dinoprostone—SLC22A8—urine—urinary bladder cancer	0.00157	0.0222	CbGeAlD
Dinoprostone—Dinoprost Tromethamine—HPGDS—urinary bladder cancer	0.00153	0.771	CrCbGaD
Dinoprostone—PTGER3—prostate gland—urinary bladder cancer	0.00146	0.0206	CbGeAlD
Dinoprostone—PTGER4—epithelium—urinary bladder cancer	0.00127	0.0179	CbGeAlD
Dinoprostone—HPGDS—prostate gland—urinary bladder cancer	0.00126	0.0178	CbGeAlD
Dinoprostone—PTGER4—smooth muscle tissue—urinary bladder cancer	0.00122	0.0172	CbGeAlD
Dinoprostone—PTGER2—urethra—urinary bladder cancer	0.00117	0.0166	CbGeAlD
Dinoprostone—PTGER4—renal system—urinary bladder cancer	0.00117	0.0166	CbGeAlD
Dinoprostone—PTGFR—prostate gland—urinary bladder cancer	0.00117	0.0165	CbGeAlD
Dinoprostone—PTGER1—renal system—urinary bladder cancer	0.00113	0.016	CbGeAlD
Dinoprostone—CYP1A2—urine—urinary bladder cancer	0.00108	0.0152	CbGeAlD
Dinoprostone—PTGER3—smooth muscle tissue—urinary bladder cancer	0.00103	0.0146	CbGeAlD
Dinoprostone—PTGIR—prostate gland—urinary bladder cancer	0.00103	0.0145	CbGeAlD
Dinoprostone—PTGER3—renal system—urinary bladder cancer	0.000994	0.014	CbGeAlD
Dinoprostone—PTGER2—female reproductive system—urinary bladder cancer	0.000958	0.0135	CbGeAlD
Dinoprostone—PTGER4—female reproductive system—urinary bladder cancer	0.00094	0.0133	CbGeAlD
Dinoprostone—HPGDS—epithelium—urinary bladder cancer	0.000926	0.0131	CbGeAlD
Dinoprostone—SLC51A—female reproductive system—urinary bladder cancer	0.000923	0.0131	CbGeAlD
Dinoprostone—PTGER1—female reproductive system—urinary bladder cancer	0.000908	0.0128	CbGeAlD
Dinoprostone—SLCO3A1—prostate gland—urinary bladder cancer	0.000907	0.0128	CbGeAlD
Dinoprostone—SLCO2A1—prostate gland—urinary bladder cancer	0.000898	0.0127	CbGeAlD
Dinoprostone—PTGER2—vagina—urinary bladder cancer	0.000866	0.0122	CbGeAlD
Dinoprostone—HPGDS—renal system—urinary bladder cancer	0.000859	0.0121	CbGeAlD
Dinoprostone—HPGDS—urethra—urinary bladder cancer	0.000844	0.0119	CbGeAlD
Dinoprostone—SLC51A—vagina—urinary bladder cancer	0.000835	0.0118	CbGeAlD
Dinoprostone—SLCO4A1—prostate gland—urinary bladder cancer	0.000826	0.0117	CbGeAlD
Dinoprostone—PTGFR—smooth muscle tissue—urinary bladder cancer	0.000825	0.0117	CbGeAlD
Dinoprostone—ABCC5—prostate gland—urinary bladder cancer	0.000821	0.0116	CbGeAlD
Dinoprostone—PTGER3—female reproductive system—urinary bladder cancer	0.000796	0.0113	CbGeAlD
Dinoprostone—PTGFR—urethra—urinary bladder cancer	0.000781	0.011	CbGeAlD
Dinoprostone—SLCO3A1—seminal vesicle—urinary bladder cancer	0.000767	0.0108	CbGeAlD
Dinoprostone—SLCO2A1—seminal vesicle—urinary bladder cancer	0.00076	0.0107	CbGeAlD
Dinoprostone—PTGIR—epithelium—urinary bladder cancer	0.000755	0.0107	CbGeAlD
Dinoprostone—PTGIR—smooth muscle tissue—urinary bladder cancer	0.000727	0.0103	CbGeAlD
Dinoprostone—SLCO1C1—renal system—urinary bladder cancer	0.000703	0.00993	CbGeAlD
Dinoprostone—PTGIR—renal system—urinary bladder cancer	0.0007	0.0099	CbGeAlD
Dinoprostone—SLCO4A1—seminal vesicle—urinary bladder cancer	0.000699	0.00988	CbGeAlD
Dinoprostone—HPGDS—female reproductive system—urinary bladder cancer	0.000688	0.00972	CbGeAlD
Dinoprostone—SLC22A11—renal system—urinary bladder cancer	0.000682	0.00965	CbGeAlD
Dinoprostone—SLC22A7—renal system—urinary bladder cancer	0.000666	0.00941	CbGeAlD
Dinoprostone—SLCO2A1—epithelium—urinary bladder cancer	0.00066	0.00933	CbGeAlD
Dinoprostone—SLCO2B1—prostate gland—urinary bladder cancer	0.000643	0.00909	CbGeAlD
Dinoprostone—PTGFR—female reproductive system—urinary bladder cancer	0.000636	0.00899	CbGeAlD
Dinoprostone—HPGDS—vagina—urinary bladder cancer	0.000622	0.00879	CbGeAlD
Dinoprostone—SLCO3A1—renal system—urinary bladder cancer	0.000618	0.00873	CbGeAlD
Dinoprostone—SLCO2A1—renal system—urinary bladder cancer	0.000612	0.00865	CbGeAlD
Dinoprostone—SLCO3A1—urethra—urinary bladder cancer	0.000607	0.00858	CbGeAlD
Dinoprostone—SLCO2A1—urethra—urinary bladder cancer	0.000601	0.0085	CbGeAlD
Dinoprostone—SLC22A2—renal system—urinary bladder cancer	0.000593	0.00838	CbGeAlD
Dinoprostone—CYP19A1—prostate gland—urinary bladder cancer	0.000577	0.00816	CbGeAlD
Dinoprostone—ABCC4—prostate gland—urinary bladder cancer	0.000569	0.00805	CbGeAlD
Dinoprostone—SLC22A8—prostate gland—urinary bladder cancer	0.000565	0.00798	CbGeAlD
Dinoprostone—SLCO4A1—renal system—urinary bladder cancer	0.000563	0.00796	CbGeAlD
Dinoprostone—PTGIR—female reproductive system—urinary bladder cancer	0.000561	0.00793	CbGeAlD
Dinoprostone—PTGER2—lymph node—urinary bladder cancer	0.00056	0.00792	CbGeAlD
Dinoprostone—SLCO4A1—urethra—urinary bladder cancer	0.000553	0.00782	CbGeAlD
Dinoprostone—PTGER4—lymph node—urinary bladder cancer	0.00055	0.00777	CbGeAlD
Dinoprostone—SLC22A11—female reproductive system—urinary bladder cancer	0.000547	0.00772	CbGeAlD
Dinoprostone—SLC51A—lymph node—urinary bladder cancer	0.00054	0.00763	CbGeAlD
Dinoprostone—SLCO1B1—renal system—urinary bladder cancer	0.000495	0.007	CbGeAlD
Dinoprostone—SLCO3A1—female reproductive system—urinary bladder cancer	0.000495	0.007	CbGeAlD
Dinoprostone—SLCO2A1—female reproductive system—urinary bladder cancer	0.00049	0.00693	CbGeAlD
Dinoprostone—CYP11A1—female reproductive system—urinary bladder cancer	0.000485	0.00686	CbGeAlD
Dinoprostone—PTGER3—lymph node—urinary bladder cancer	0.000466	0.00658	CbGeAlD
Dinoprostone—Dihomo-gamma-linolenic acid—PTGS2—urinary bladder cancer	0.000454	0.229	CrCbGaD
Dinoprostone—SLCO4A1—female reproductive system—urinary bladder cancer	0.000451	0.00637	CbGeAlD
Dinoprostone—SLCO3A1—vagina—urinary bladder cancer	0.000448	0.00633	CbGeAlD
Dinoprostone—SLCO2A1—vagina—urinary bladder cancer	0.000443	0.00627	CbGeAlD
Dinoprostone—SLCO2B1—renal system—urinary bladder cancer	0.000438	0.00619	CbGeAlD
Dinoprostone—SLC22A1—renal system—urinary bladder cancer	0.000419	0.00592	CbGeAlD
Dinoprostone—SLCO4A1—vagina—urinary bladder cancer	0.000408	0.00576	CbGeAlD
Dinoprostone—ABCC5—vagina—urinary bladder cancer	0.000405	0.00573	CbGeAlD
Dinoprostone—SLCO1A2—renal system—urinary bladder cancer	0.000403	0.0057	CbGeAlD
Dinoprostone—HPGDS—lymph node—urinary bladder cancer	0.000402	0.00569	CbGeAlD
Dinoprostone—SLCO1B1—female reproductive system—urinary bladder cancer	0.000397	0.00561	CbGeAlD
Dinoprostone—ABCC4—renal system—urinary bladder cancer	0.000388	0.00548	CbGeAlD
Dinoprostone—SLC22A8—renal system—urinary bladder cancer	0.000385	0.00544	CbGeAlD
Dinoprostone—PTGFR—lymph node—urinary bladder cancer	0.000372	0.00526	CbGeAlD
Dinoprostone—SLCO2B1—female reproductive system—urinary bladder cancer	0.000351	0.00496	CbGeAlD
Dinoprostone—SLCO1C1—lymph node—urinary bladder cancer	0.000329	0.00465	CbGeAlD
Dinoprostone—PTGIR—lymph node—urinary bladder cancer	0.000328	0.00464	CbGeAlD
Dinoprostone—CYP19A1—female reproductive system—urinary bladder cancer	0.000315	0.00445	CbGeAlD
Dinoprostone—ABCC4—female reproductive system—urinary bladder cancer	0.000311	0.00439	CbGeAlD
Dinoprostone—SLC22A1—vagina—urinary bladder cancer	0.000303	0.00429	CbGeAlD
Dinoprostone—SLCO3A1—lymph node—urinary bladder cancer	0.00029	0.00409	CbGeAlD
Dinoprostone—SLCO2A1—lymph node—urinary bladder cancer	0.000287	0.00405	CbGeAlD
Dinoprostone—CYP11A1—lymph node—urinary bladder cancer	0.000284	0.00401	CbGeAlD
Dinoprostone—SLCO4A1—lymph node—urinary bladder cancer	0.000264	0.00373	CbGeAlD
Dinoprostone—CYP1A2—renal system—urinary bladder cancer	0.000264	0.00373	CbGeAlD
Dinoprostone—ABCC5—lymph node—urinary bladder cancer	0.000262	0.00371	CbGeAlD
Dinoprostone—SLCO2B1—lymph node—urinary bladder cancer	0.000205	0.0029	CbGeAlD
Dinoprostone—Vaginal inflammation—Epirubicin—urinary bladder cancer	0.000194	0.00336	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000191	0.00331	CcSEcCtD
Dinoprostone—Myocardial infarction—Etoposide—urinary bladder cancer	0.00019	0.00329	CcSEcCtD
Dinoprostone—Inflammation—Doxorubicin—urinary bladder cancer	0.000185	0.00321	CcSEcCtD
Dinoprostone—Angiopathy—Gemcitabine—urinary bladder cancer	0.000185	0.0032	CcSEcCtD
Dinoprostone—CYP19A1—lymph node—urinary bladder cancer	0.000184	0.00261	CbGeAlD
Dinoprostone—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000184	0.00319	CcSEcCtD
Dinoprostone—Cough—Thiotepa—urinary bladder cancer	0.000184	0.00319	CcSEcCtD
Dinoprostone—Vaginal infection—Epirubicin—urinary bladder cancer	0.000183	0.00317	CcSEcCtD
Dinoprostone—Chills—Gemcitabine—urinary bladder cancer	0.000183	0.00317	CcSEcCtD
Dinoprostone—Hypertension—Thiotepa—urinary bladder cancer	0.000182	0.00315	CcSEcCtD
Dinoprostone—Arrhythmia—Gemcitabine—urinary bladder cancer	0.000182	0.00315	CcSEcCtD
Dinoprostone—ABCC4—lymph node—urinary bladder cancer	0.000182	0.00257	CbGeAlD
Dinoprostone—Vaginal inflammation—Doxorubicin—urinary bladder cancer	0.00018	0.00311	CcSEcCtD
Dinoprostone—Hiccups—Doxorubicin—urinary bladder cancer	0.00018	0.00311	CcSEcCtD
Dinoprostone—Arthralgia—Thiotepa—urinary bladder cancer	0.000179	0.00311	CcSEcCtD
Dinoprostone—Myalgia—Thiotepa—urinary bladder cancer	0.000179	0.00311	CcSEcCtD
Dinoprostone—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000179	0.0031	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Epirubicin—urinary bladder cancer	0.000178	0.00309	CcSEcCtD
Dinoprostone—Flushing—Cisplatin—urinary bladder cancer	0.000176	0.00305	CcSEcCtD
Dinoprostone—Back pain—Gemcitabine—urinary bladder cancer	0.000171	0.00297	CcSEcCtD
Dinoprostone—Immune system disorder—Cisplatin—urinary bladder cancer	0.000171	0.00297	CcSEcCtD
Dinoprostone—Hypertonia—Epirubicin—urinary bladder cancer	0.00017	0.00295	CcSEcCtD
Dinoprostone—Arrhythmia—Cisplatin—urinary bladder cancer	0.00017	0.00294	CcSEcCtD
Dinoprostone—Vaginal infection—Doxorubicin—urinary bladder cancer	0.00017	0.00294	CcSEcCtD
Dinoprostone—Tachycardia—Thiotepa—urinary bladder cancer	0.000168	0.00291	CcSEcCtD
Dinoprostone—Cramps of lower extremities—Doxorubicin—urinary bladder cancer	0.000165	0.00286	CcSEcCtD
Dinoprostone—Vision blurred—Fluorouracil—urinary bladder cancer	0.000164	0.00285	CcSEcCtD
Dinoprostone—Flushing—Etoposide—urinary bladder cancer	0.000161	0.0028	CcSEcCtD
Dinoprostone—Muscle spasms—Cisplatin—urinary bladder cancer	0.000159	0.00275	CcSEcCtD
Dinoprostone—Angiopathy—Etoposide—urinary bladder cancer	0.000158	0.00273	CcSEcCtD
Dinoprostone—Hypertonia—Doxorubicin—urinary bladder cancer	0.000157	0.00273	CcSEcCtD
Dinoprostone—Immune system disorder—Etoposide—urinary bladder cancer	0.000157	0.00272	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000157	0.00271	CcSEcCtD
Dinoprostone—Eye pain—Epirubicin—urinary bladder cancer	0.000156	0.0027	CcSEcCtD
Dinoprostone—Chills—Etoposide—urinary bladder cancer	0.000156	0.0027	CcSEcCtD
Dinoprostone—Vision blurred—Cisplatin—urinary bladder cancer	0.000156	0.0027	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.000156	0.00269	CcSEcCtD
Dinoprostone—Tremor—Cisplatin—urinary bladder cancer	0.000155	0.00268	CcSEcCtD
Dinoprostone—Cough—Gemcitabine—urinary bladder cancer	0.000155	0.00268	CcSEcCtD
Dinoprostone—Paraesthesia—Thiotepa—urinary bladder cancer	0.000154	0.00268	CcSEcCtD
Dinoprostone—Hypertension—Gemcitabine—urinary bladder cancer	0.000153	0.00265	CcSEcCtD
Dinoprostone—Arthralgia—Gemcitabine—urinary bladder cancer	0.000151	0.00261	CcSEcCtD
Dinoprostone—Myalgia—Gemcitabine—urinary bladder cancer	0.000151	0.00261	CcSEcCtD
Dinoprostone—Chest pain—Gemcitabine—urinary bladder cancer	0.000151	0.00261	CcSEcCtD
Dinoprostone—Hot flush—Epirubicin—urinary bladder cancer	0.000151	0.00261	CcSEcCtD
Dinoprostone—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.000149	0.00259	CcSEcCtD
Dinoprostone—Myalgia—Fluorouracil—urinary bladder cancer	0.000148	0.00257	CcSEcCtD
Dinoprostone—Chest pain—Fluorouracil—urinary bladder cancer	0.000148	0.00257	CcSEcCtD
Dinoprostone—Pain—Thiotepa—urinary bladder cancer	0.000147	0.00255	CcSEcCtD
Dinoprostone—Back pain—Etoposide—urinary bladder cancer	0.000146	0.00254	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.000146	0.00252	CcSEcCtD
Dinoprostone—Muscle spasms—Etoposide—urinary bladder cancer	0.000145	0.00252	CcSEcCtD
Dinoprostone—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000145	0.00251	CcSEcCtD
Dinoprostone—Eye pain—Doxorubicin—urinary bladder cancer	0.000144	0.0025	CcSEcCtD
Dinoprostone—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000142	0.00246	CcSEcCtD
Dinoprostone—Myalgia—Cisplatin—urinary bladder cancer	0.000141	0.00244	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000141	0.00244	CcSEcCtD
Dinoprostone—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00014	0.00242	CcSEcCtD
Dinoprostone—Hot flush—Doxorubicin—urinary bladder cancer	0.000139	0.00241	CcSEcCtD
Dinoprostone—Tachycardia—Fluorouracil—urinary bladder cancer	0.000139	0.0024	CcSEcCtD
Dinoprostone—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.000138	0.00239	CcSEcCtD
Dinoprostone—Body temperature increased—Thiotepa—urinary bladder cancer	0.000136	0.00236	CcSEcCtD
Dinoprostone—Abdominal pain—Thiotepa—urinary bladder cancer	0.000136	0.00236	CcSEcCtD
Dinoprostone—Hypotension—Gemcitabine—urinary bladder cancer	0.000135	0.00234	CcSEcCtD
Dinoprostone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000135	0.00234	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000135	0.00233	CcSEcCtD
Dinoprostone—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000134	0.00232	CcSEcCtD
Dinoprostone—Loss of consciousness—Etoposide—urinary bladder cancer	0.000133	0.0023	CcSEcCtD
Dinoprostone—Hypotension—Fluorouracil—urinary bladder cancer	0.000133	0.0023	CcSEcCtD
Dinoprostone—Cough—Etoposide—urinary bladder cancer	0.000132	0.00229	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000132	0.00228	CcSEcCtD
Dinoprostone—Tachycardia—Cisplatin—urinary bladder cancer	0.000132	0.00228	CcSEcCtD
Dinoprostone—Dehydration—Epirubicin—urinary bladder cancer	0.000131	0.00227	CcSEcCtD
Dinoprostone—Hypertension—Etoposide—urinary bladder cancer	0.000131	0.00226	CcSEcCtD
Dinoprostone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00013	0.00226	CcSEcCtD
Dinoprostone—Asthma—Methotrexate—urinary bladder cancer	0.00013	0.00225	CcSEcCtD
Dinoprostone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00013	0.00225	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00013	0.00225	CcSEcCtD
Dinoprostone—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000129	0.00223	CcSEcCtD
Dinoprostone—Chest pain—Etoposide—urinary bladder cancer	0.000129	0.00223	CcSEcCtD
Dinoprostone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000128	0.00221	CcSEcCtD
Dinoprostone—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000127	0.0022	CcSEcCtD
Dinoprostone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000127	0.0022	CcSEcCtD
Dinoprostone—Hypotension—Cisplatin—urinary bladder cancer	0.000126	0.00218	CcSEcCtD
Dinoprostone—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000124	0.00215	CcSEcCtD
Dinoprostone—Pain—Gemcitabine—urinary bladder cancer	0.000124	0.00214	CcSEcCtD
Dinoprostone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000124	0.00214	CcSEcCtD
Dinoprostone—Asthenia—Thiotepa—urinary bladder cancer	0.000123	0.00214	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000123	0.00213	CcSEcCtD
Dinoprostone—Asthma—Epirubicin—urinary bladder cancer	0.000122	0.00211	CcSEcCtD
Dinoprostone—Pain—Fluorouracil—urinary bladder cancer	0.000122	0.00211	CcSEcCtD
Dinoprostone—Dehydration—Doxorubicin—urinary bladder cancer	0.000121	0.0021	CcSEcCtD
Dinoprostone—Paraesthesia—Cisplatin—urinary bladder cancer	0.000121	0.0021	CcSEcCtD
Dinoprostone—Tachycardia—Etoposide—urinary bladder cancer	0.000121	0.00209	CcSEcCtD
Dinoprostone—Dyspnoea—Cisplatin—urinary bladder cancer	0.00012	0.00208	CcSEcCtD
Dinoprostone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000119	0.00207	CcSEcCtD
Dinoprostone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000118	0.00204	CcSEcCtD
Dinoprostone—Hypotension—Etoposide—urinary bladder cancer	0.000115	0.002	CcSEcCtD
Dinoprostone—Pain—Cisplatin—urinary bladder cancer	0.000115	0.002	CcSEcCtD
Dinoprostone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000114	0.00198	CcSEcCtD
Dinoprostone—Dizziness—Thiotepa—urinary bladder cancer	0.000114	0.00197	CcSEcCtD
Dinoprostone—Asthma—Doxorubicin—urinary bladder cancer	0.000113	0.00195	CcSEcCtD
Dinoprostone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000112	0.00195	CcSEcCtD
Dinoprostone—Paraesthesia—Etoposide—urinary bladder cancer	0.000111	0.00192	CcSEcCtD
Dinoprostone—Dyspnoea—Etoposide—urinary bladder cancer	0.00011	0.00191	CcSEcCtD
Dinoprostone—Vomiting—Thiotepa—urinary bladder cancer	0.000109	0.00189	CcSEcCtD
Dinoprostone—Rash—Thiotepa—urinary bladder cancer	0.000108	0.00188	CcSEcCtD
Dinoprostone—Dermatitis—Thiotepa—urinary bladder cancer	0.000108	0.00188	CcSEcCtD
Dinoprostone—Headache—Thiotepa—urinary bladder cancer	0.000108	0.00187	CcSEcCtD
Dinoprostone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000107	0.00185	CcSEcCtD
Dinoprostone—Pain—Etoposide—urinary bladder cancer	0.000106	0.00183	CcSEcCtD
Dinoprostone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000105	0.00182	CcSEcCtD
Dinoprostone—Asthenia—Gemcitabine—urinary bladder cancer	0.000104	0.0018	CcSEcCtD
Dinoprostone—Pharyngitis—Methotrexate—urinary bladder cancer	0.000103	0.00179	CcSEcCtD
Dinoprostone—Nausea—Thiotepa—urinary bladder cancer	0.000102	0.00177	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000101	0.00175	CcSEcCtD
Dinoprostone—Hypersensitivity—Cisplatin—urinary bladder cancer	9.93e-05	0.00172	CcSEcCtD
Dinoprostone—Diarrhoea—Gemcitabine—urinary bladder cancer	9.9e-05	0.00171	CcSEcCtD
Dinoprostone—Abdominal pain—Etoposide—urinary bladder cancer	9.76e-05	0.00169	CcSEcCtD
Dinoprostone—Body temperature increased—Etoposide—urinary bladder cancer	9.76e-05	0.00169	CcSEcCtD
Dinoprostone—Diarrhoea—Fluorouracil—urinary bladder cancer	9.73e-05	0.00169	CcSEcCtD
Dinoprostone—Asthenia—Cisplatin—urinary bladder cancer	9.67e-05	0.00168	CcSEcCtD
Dinoprostone—Pharyngitis—Epirubicin—urinary bladder cancer	9.67e-05	0.00168	CcSEcCtD
Dinoprostone—Angiopathy—Methotrexate—urinary bladder cancer	9.45e-05	0.00164	CcSEcCtD
Dinoprostone—Immune system disorder—Methotrexate—urinary bladder cancer	9.41e-05	0.00163	CcSEcCtD
Dinoprostone—Dizziness—Fluorouracil—urinary bladder cancer	9.4e-05	0.00163	CcSEcCtD
Dinoprostone—Chills—Methotrexate—urinary bladder cancer	9.34e-05	0.00162	CcSEcCtD
Dinoprostone—Diarrhoea—Cisplatin—urinary bladder cancer	9.22e-05	0.0016	CcSEcCtD
Dinoprostone—Vomiting—Gemcitabine—urinary bladder cancer	9.2e-05	0.00159	CcSEcCtD
Dinoprostone—Rash—Gemcitabine—urinary bladder cancer	9.12e-05	0.00158	CcSEcCtD
Dinoprostone—Dermatitis—Gemcitabine—urinary bladder cancer	9.11e-05	0.00158	CcSEcCtD
Dinoprostone—Hypersensitivity—Etoposide—urinary bladder cancer	9.1e-05	0.00158	CcSEcCtD
Dinoprostone—Headache—Gemcitabine—urinary bladder cancer	9.06e-05	0.00157	CcSEcCtD
Dinoprostone—Flushing—Epirubicin—urinary bladder cancer	9.04e-05	0.00157	CcSEcCtD
Dinoprostone—Vomiting—Fluorouracil—urinary bladder cancer	9.04e-05	0.00157	CcSEcCtD
Dinoprostone—Rash—Fluorouracil—urinary bladder cancer	8.97e-05	0.00155	CcSEcCtD
Dinoprostone—Dermatitis—Fluorouracil—urinary bladder cancer	8.96e-05	0.00155	CcSEcCtD
Dinoprostone—Pharyngitis—Doxorubicin—urinary bladder cancer	8.95e-05	0.00155	CcSEcCtD
Dinoprostone—Headache—Fluorouracil—urinary bladder cancer	8.91e-05	0.00154	CcSEcCtD
Dinoprostone—Asthenia—Etoposide—urinary bladder cancer	8.86e-05	0.00154	CcSEcCtD
Dinoprostone—Angiopathy—Epirubicin—urinary bladder cancer	8.84e-05	0.00153	CcSEcCtD
Dinoprostone—Immune system disorder—Epirubicin—urinary bladder cancer	8.8e-05	0.00153	CcSEcCtD
Dinoprostone—Back pain—Methotrexate—urinary bladder cancer	8.77e-05	0.00152	CcSEcCtD
Dinoprostone—Chills—Epirubicin—urinary bladder cancer	8.74e-05	0.00152	CcSEcCtD
Dinoprostone—Arrhythmia—Epirubicin—urinary bladder cancer	8.7e-05	0.00151	CcSEcCtD
Dinoprostone—Nausea—Gemcitabine—urinary bladder cancer	8.59e-05	0.00149	CcSEcCtD
Dinoprostone—Vomiting—Cisplatin—urinary bladder cancer	8.57e-05	0.00149	CcSEcCtD
Dinoprostone—Vision blurred—Methotrexate—urinary bladder cancer	8.54e-05	0.00148	CcSEcCtD
Dinoprostone—Rash—Cisplatin—urinary bladder cancer	8.5e-05	0.00147	CcSEcCtD
Dinoprostone—Dermatitis—Cisplatin—urinary bladder cancer	8.49e-05	0.00147	CcSEcCtD
Dinoprostone—Diarrhoea—Etoposide—urinary bladder cancer	8.45e-05	0.00146	CcSEcCtD
Dinoprostone—Nausea—Fluorouracil—urinary bladder cancer	8.45e-05	0.00146	CcSEcCtD
Dinoprostone—Flushing—Doxorubicin—urinary bladder cancer	8.37e-05	0.00145	CcSEcCtD
Dinoprostone—Tension—Epirubicin—urinary bladder cancer	8.32e-05	0.00144	CcSEcCtD
Dinoprostone—Back pain—Epirubicin—urinary bladder cancer	8.21e-05	0.00142	CcSEcCtD
Dinoprostone—Angiopathy—Doxorubicin—urinary bladder cancer	8.18e-05	0.00142	CcSEcCtD
Dinoprostone—Dizziness—Etoposide—urinary bladder cancer	8.17e-05	0.00142	CcSEcCtD
Dinoprostone—Muscle spasms—Epirubicin—urinary bladder cancer	8.16e-05	0.00141	CcSEcCtD
Dinoprostone—Immune system disorder—Doxorubicin—urinary bladder cancer	8.14e-05	0.00141	CcSEcCtD
Dinoprostone—Chills—Doxorubicin—urinary bladder cancer	8.09e-05	0.0014	CcSEcCtD
Dinoprostone—Arrhythmia—Doxorubicin—urinary bladder cancer	8.05e-05	0.0014	CcSEcCtD
Dinoprostone—Nausea—Cisplatin—urinary bladder cancer	8.01e-05	0.00139	CcSEcCtD
Dinoprostone—Vision blurred—Epirubicin—urinary bladder cancer	7.99e-05	0.00139	CcSEcCtD
Dinoprostone—Cough—Methotrexate—urinary bladder cancer	7.91e-05	0.00137	CcSEcCtD
Dinoprostone—Vomiting—Etoposide—urinary bladder cancer	7.85e-05	0.00136	CcSEcCtD
Dinoprostone—Rash—Etoposide—urinary bladder cancer	7.79e-05	0.00135	CcSEcCtD
Dinoprostone—Dermatitis—Etoposide—urinary bladder cancer	7.78e-05	0.00135	CcSEcCtD
Dinoprostone—Headache—Etoposide—urinary bladder cancer	7.74e-05	0.00134	CcSEcCtD
Dinoprostone—Myalgia—Methotrexate—urinary bladder cancer	7.72e-05	0.00134	CcSEcCtD
Dinoprostone—Chest pain—Methotrexate—urinary bladder cancer	7.72e-05	0.00134	CcSEcCtD
Dinoprostone—Arthralgia—Methotrexate—urinary bladder cancer	7.72e-05	0.00134	CcSEcCtD
Dinoprostone—Tension—Doxorubicin—urinary bladder cancer	7.7e-05	0.00133	CcSEcCtD
Dinoprostone—Syncope—Epirubicin—urinary bladder cancer	7.61e-05	0.00132	CcSEcCtD
Dinoprostone—Back pain—Doxorubicin—urinary bladder cancer	7.59e-05	0.00132	CcSEcCtD
Dinoprostone—Muscle spasms—Doxorubicin—urinary bladder cancer	7.55e-05	0.00131	CcSEcCtD
Dinoprostone—Loss of consciousness—Epirubicin—urinary bladder cancer	7.46e-05	0.00129	CcSEcCtD
Dinoprostone—Cough—Epirubicin—urinary bladder cancer	7.4e-05	0.00128	CcSEcCtD
Dinoprostone—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.4e-05	0.00128	CcSEcCtD
Dinoprostone—Vision blurred—Doxorubicin—urinary bladder cancer	7.4e-05	0.00128	CcSEcCtD
Dinoprostone—Nausea—Etoposide—urinary bladder cancer	7.34e-05	0.00127	CcSEcCtD
Dinoprostone—Hypertension—Epirubicin—urinary bladder cancer	7.32e-05	0.00127	CcSEcCtD
Dinoprostone—Arthralgia—Epirubicin—urinary bladder cancer	7.22e-05	0.00125	CcSEcCtD
Dinoprostone—Chest pain—Epirubicin—urinary bladder cancer	7.22e-05	0.00125	CcSEcCtD
Dinoprostone—Myalgia—Epirubicin—urinary bladder cancer	7.22e-05	0.00125	CcSEcCtD
Dinoprostone—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.15e-05	0.00124	CcSEcCtD
Dinoprostone—Syncope—Doxorubicin—urinary bladder cancer	7.04e-05	0.00122	CcSEcCtD
Dinoprostone—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.92e-05	0.0012	CcSEcCtD
Dinoprostone—Hypotension—Methotrexate—urinary bladder cancer	6.91e-05	0.0012	CcSEcCtD
Dinoprostone—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.9e-05	0.0012	CcSEcCtD
Dinoprostone—Cough—Doxorubicin—urinary bladder cancer	6.85e-05	0.00119	CcSEcCtD
Dinoprostone—Shock—Epirubicin—urinary bladder cancer	6.81e-05	0.00118	CcSEcCtD
Dinoprostone—Hypertension—Doxorubicin—urinary bladder cancer	6.78e-05	0.00117	CcSEcCtD
Dinoprostone—Tachycardia—Epirubicin—urinary bladder cancer	6.76e-05	0.00117	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.74e-05	0.00117	CcSEcCtD
Dinoprostone—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.69e-05	0.00116	CcSEcCtD
Dinoprostone—Arthralgia—Doxorubicin—urinary bladder cancer	6.68e-05	0.00116	CcSEcCtD
Dinoprostone—Myalgia—Doxorubicin—urinary bladder cancer	6.68e-05	0.00116	CcSEcCtD
Dinoprostone—Chest pain—Doxorubicin—urinary bladder cancer	6.68e-05	0.00116	CcSEcCtD
Dinoprostone—Paraesthesia—Methotrexate—urinary bladder cancer	6.64e-05	0.00115	CcSEcCtD
Dinoprostone—Dyspnoea—Methotrexate—urinary bladder cancer	6.6e-05	0.00114	CcSEcCtD
Dinoprostone—Hypotension—Epirubicin—urinary bladder cancer	6.47e-05	0.00112	CcSEcCtD
Dinoprostone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.41e-05	0.00111	CcSEcCtD
Dinoprostone—Pain—Methotrexate—urinary bladder cancer	6.33e-05	0.0011	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.31e-05	0.00109	CcSEcCtD
Dinoprostone—Shock—Doxorubicin—urinary bladder cancer	6.3e-05	0.00109	CcSEcCtD
Dinoprostone—Tachycardia—Doxorubicin—urinary bladder cancer	6.25e-05	0.00108	CcSEcCtD
Dinoprostone—Paraesthesia—Epirubicin—urinary bladder cancer	6.22e-05	0.00108	CcSEcCtD
Dinoprostone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.19e-05	0.00107	CcSEcCtD
Dinoprostone—Dyspnoea—Epirubicin—urinary bladder cancer	6.17e-05	0.00107	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.05e-05	0.00105	CcSEcCtD
Dinoprostone—Hypotension—Doxorubicin—urinary bladder cancer	5.99e-05	0.00104	CcSEcCtD
Dinoprostone—Pain—Epirubicin—urinary bladder cancer	5.92e-05	0.00103	CcSEcCtD
Dinoprostone—Abdominal pain—Methotrexate—urinary bladder cancer	5.85e-05	0.00101	CcSEcCtD
Dinoprostone—Body temperature increased—Methotrexate—urinary bladder cancer	5.85e-05	0.00101	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.84e-05	0.00101	CcSEcCtD
Dinoprostone—Paraesthesia—Doxorubicin—urinary bladder cancer	5.75e-05	0.000997	CcSEcCtD
Dinoprostone—Dyspnoea—Doxorubicin—urinary bladder cancer	5.71e-05	0.00099	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.66e-05	0.000981	CcSEcCtD
Dinoprostone—Pain—Doxorubicin—urinary bladder cancer	5.48e-05	0.000949	CcSEcCtD
Dinoprostone—Abdominal pain—Epirubicin—urinary bladder cancer	5.47e-05	0.000948	CcSEcCtD
Dinoprostone—Body temperature increased—Epirubicin—urinary bladder cancer	5.47e-05	0.000948	CcSEcCtD
Dinoprostone—Hypersensitivity—Methotrexate—urinary bladder cancer	5.45e-05	0.000944	CcSEcCtD
Dinoprostone—Asthenia—Methotrexate—urinary bladder cancer	5.31e-05	0.00092	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.24e-05	0.000908	CcSEcCtD
Dinoprostone—Hypersensitivity—Epirubicin—urinary bladder cancer	5.1e-05	0.000884	CcSEcCtD
Dinoprostone—Abdominal pain—Doxorubicin—urinary bladder cancer	5.06e-05	0.000877	CcSEcCtD
Dinoprostone—Body temperature increased—Doxorubicin—urinary bladder cancer	5.06e-05	0.000877	CcSEcCtD
Dinoprostone—Diarrhoea—Methotrexate—urinary bladder cancer	5.06e-05	0.000877	CcSEcCtD
Dinoprostone—Asthenia—Epirubicin—urinary bladder cancer	4.97e-05	0.000861	CcSEcCtD
Dinoprostone—Dizziness—Methotrexate—urinary bladder cancer	4.89e-05	0.000848	CcSEcCtD
Dinoprostone—Diarrhoea—Epirubicin—urinary bladder cancer	4.74e-05	0.000821	CcSEcCtD
Dinoprostone—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.72e-05	0.000818	CcSEcCtD
Dinoprostone—Vomiting—Methotrexate—urinary bladder cancer	4.7e-05	0.000815	CcSEcCtD
Dinoprostone—Rash—Methotrexate—urinary bladder cancer	4.66e-05	0.000808	CcSEcCtD
Dinoprostone—Dermatitis—Methotrexate—urinary bladder cancer	4.66e-05	0.000807	CcSEcCtD
Dinoprostone—Headache—Methotrexate—urinary bladder cancer	4.63e-05	0.000803	CcSEcCtD
Dinoprostone—Asthenia—Doxorubicin—urinary bladder cancer	4.6e-05	0.000796	CcSEcCtD
Dinoprostone—Dizziness—Epirubicin—urinary bladder cancer	4.58e-05	0.000793	CcSEcCtD
Dinoprostone—Vomiting—Epirubicin—urinary bladder cancer	4.4e-05	0.000763	CcSEcCtD
Dinoprostone—Nausea—Methotrexate—urinary bladder cancer	4.39e-05	0.000761	CcSEcCtD
Dinoprostone—Diarrhoea—Doxorubicin—urinary bladder cancer	4.38e-05	0.000759	CcSEcCtD
Dinoprostone—Rash—Epirubicin—urinary bladder cancer	4.37e-05	0.000756	CcSEcCtD
Dinoprostone—Dermatitis—Epirubicin—urinary bladder cancer	4.36e-05	0.000756	CcSEcCtD
Dinoprostone—Headache—Epirubicin—urinary bladder cancer	4.34e-05	0.000752	CcSEcCtD
Dinoprostone—Dizziness—Doxorubicin—urinary bladder cancer	4.24e-05	0.000734	CcSEcCtD
Dinoprostone—Nausea—Epirubicin—urinary bladder cancer	4.11e-05	0.000713	CcSEcCtD
Dinoprostone—Vomiting—Doxorubicin—urinary bladder cancer	4.07e-05	0.000706	CcSEcCtD
Dinoprostone—Rash—Doxorubicin—urinary bladder cancer	4.04e-05	0.0007	CcSEcCtD
Dinoprostone—Dermatitis—Doxorubicin—urinary bladder cancer	4.04e-05	0.000699	CcSEcCtD
Dinoprostone—Headache—Doxorubicin—urinary bladder cancer	4.01e-05	0.000695	CcSEcCtD
Dinoprostone—Nausea—Doxorubicin—urinary bladder cancer	3.8e-05	0.000659	CcSEcCtD
Dinoprostone—CYP11A1—Metabolism—ERCC2—urinary bladder cancer	1.01e-05	0.000155	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CREBBP—urinary bladder cancer	1.01e-05	0.000155	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—EP300—urinary bladder cancer	1.01e-05	0.000155	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—RRM2—urinary bladder cancer	1e-05	0.000154	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—HPGDS—urinary bladder cancer	9.97e-06	0.000153	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—ENO2—urinary bladder cancer	9.97e-06	0.000153	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.95e-06	0.000153	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—NAT1—urinary bladder cancer	9.93e-06	0.000153	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	9.93e-06	0.000153	CbGpPWpGaD
Dinoprostone—SLCO1B1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.88e-06	0.000152	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—FGFR3—urinary bladder cancer	9.84e-06	0.000151	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—EP300—urinary bladder cancer	9.82e-06	0.000151	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—SRC—urinary bladder cancer	9.79e-06	0.000151	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.77e-06	0.00015	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GSTT1—urinary bladder cancer	9.67e-06	0.000149	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CXCL8—urinary bladder cancer	9.64e-06	0.000148	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—FGFR3—urinary bladder cancer	9.63e-06	0.000148	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—FGFR3—urinary bladder cancer	9.63e-06	0.000148	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—HRAS—urinary bladder cancer	9.58e-06	0.000147	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—ESR1—urinary bladder cancer	9.56e-06	0.000147	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	9.55e-06	0.000147	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—SRC—urinary bladder cancer	9.55e-06	0.000147	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—MTHFR—urinary bladder cancer	9.48e-06	0.000146	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—ERBB2—urinary bladder cancer	9.38e-06	0.000144	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—ESR1—urinary bladder cancer	9.36e-06	0.000144	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—ESR1—urinary bladder cancer	9.36e-06	0.000144	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—HPGDS—urinary bladder cancer	9.3e-06	0.000143	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—ENO2—urinary bladder cancer	9.3e-06	0.000143	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—NQO1—urinary bladder cancer	9.27e-06	0.000143	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—IL2—urinary bladder cancer	9.21e-06	0.000142	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—RHOA—urinary bladder cancer	9.11e-06	0.00014	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	9.08e-06	0.00014	CbGpPWpGaD
Dinoprostone—SLC22A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.06e-06	0.000139	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GSTT1—urinary bladder cancer	9.02e-06	0.000139	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9e-06	0.000138	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CCND1—urinary bladder cancer	8.98e-06	0.000138	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CXCL8—urinary bladder cancer	8.9e-06	0.000137	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling by GPCR—HRAS—urinary bladder cancer	8.84e-06	0.000136	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PPARG—urinary bladder cancer	8.78e-06	0.000135	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—NQO1—urinary bladder cancer	8.77e-06	0.000135	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—MYC—urinary bladder cancer	8.77e-06	0.000135	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MMP9—urinary bladder cancer	8.72e-06	0.000134	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—CDKN1A—urinary bladder cancer	8.69e-06	0.000134	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.68e-06	0.000133	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—PTEN—urinary bladder cancer	8.67e-06	0.000133	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—EGFR—urinary bladder cancer	8.58e-06	0.000132	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—GSTP1—urinary bladder cancer	8.56e-06	0.000132	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.51e-06	0.000131	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—IL2—urinary bladder cancer	8.5e-06	0.000131	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.44e-06	0.00013	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—CREBBP—urinary bladder cancer	8.43e-06	0.00013	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—ERBB2—urinary bladder cancer	8.43e-06	0.00013	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CREBBP—urinary bladder cancer	8.38e-06	0.000129	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CCND1—urinary bladder cancer	8.29e-06	0.000127	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.28e-06	0.000127	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IGF1—urinary bladder cancer	8.27e-06	0.000127	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—EP300—urinary bladder cancer	8.27e-06	0.000127	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PTGS2—urinary bladder cancer	8.25e-06	0.000127	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—EGFR—urinary bladder cancer	8.23e-06	0.000127	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CREBBP—urinary bladder cancer	8.2e-06	0.000126	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CREBBP—urinary bladder cancer	8.2e-06	0.000126	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	8.18e-06	0.000126	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—KRAS—urinary bladder cancer	8.11e-06	0.000125	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IGF1—urinary bladder cancer	8.1e-06	0.000125	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IGF1—urinary bladder cancer	8.1e-06	0.000125	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—EGFR—urinary bladder cancer	8.06e-06	0.000124	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—EGFR—urinary bladder cancer	8.06e-06	0.000124	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MMP9—urinary bladder cancer	8.05e-06	0.000124	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—SRC—urinary bladder cancer	8.04e-06	0.000124	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—NQO1—urinary bladder cancer	8.04e-06	0.000124	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—CDKN1A—urinary bladder cancer	8.02e-06	0.000123	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—PTEN—urinary bladder cancer	8e-06	0.000123	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—TYMS—urinary bladder cancer	7.96e-06	0.000122	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—KRAS—urinary bladder cancer	7.91e-06	0.000122	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—GSTM1—urinary bladder cancer	7.86e-06	0.000121	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—NCOR1—urinary bladder cancer	7.86e-06	0.000121	CbGpPWpGaD
Dinoprostone—SLC22A2—Neuronal System—HRAS—urinary bladder cancer	7.85e-06	0.000121	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.85e-06	0.000121	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—KRAS—urinary bladder cancer	7.78e-06	0.00012	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—GSTP1—urinary bladder cancer	7.73e-06	0.000119	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	7.72e-06	0.000119	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PPARG—urinary bladder cancer	7.69e-06	0.000118	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—EP300—urinary bladder cancer	7.63e-06	0.000117	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—KRAS—urinary bladder cancer	7.61e-06	0.000117	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—KRAS—urinary bladder cancer	7.61e-06	0.000117	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—RHOA—urinary bladder cancer	7.58e-06	0.000117	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—GPX1—urinary bladder cancer	7.53e-06	0.000116	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	7.53e-06	0.000116	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—NQO1—urinary bladder cancer	7.49e-06	0.000115	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.48e-06	0.000115	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.42e-06	0.000114	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—SRC—urinary bladder cancer	7.42e-06	0.000114	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—RHOA—urinary bladder cancer	7.42e-06	0.000114	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—RHOA—urinary bladder cancer	7.42e-06	0.000114	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—ERCC2—urinary bladder cancer	7.39e-06	0.000114	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—CREBBP—urinary bladder cancer	7.39e-06	0.000114	CbGpPWpGaD
Dinoprostone—SLC22A1—Neuronal System—HRAS—urinary bladder cancer	7.32e-06	0.000113	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—GSTP1—urinary bladder cancer	7.32e-06	0.000113	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—CDKN1A—urinary bladder cancer	7.21e-06	0.000111	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—TP53—urinary bladder cancer	7.2e-06	0.000111	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—MYC—urinary bladder cancer	7.2e-06	0.000111	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—PTEN—urinary bladder cancer	7.19e-06	0.000111	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—TYMS—urinary bladder cancer	7.19e-06	0.000111	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—GSTM1—urinary bladder cancer	7.11e-06	0.000109	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—NCOR1—urinary bladder cancer	7.11e-06	0.000109	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.08e-06	0.000109	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—EGFR—urinary bladder cancer	7.05e-06	0.000108	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—TP53—urinary bladder cancer	7.03e-06	0.000108	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—ERBB2—urinary bladder cancer	7.02e-06	0.000108	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	6.95e-06	0.000107	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PTGS2—urinary bladder cancer	6.91e-06	0.000106	CbGpPWpGaD
Dinoprostone—PTGER4—Signaling Pathways—HRAS—urinary bladder cancer	6.89e-06	0.000106	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—ERBB2—urinary bladder cancer	6.87e-06	0.000106	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—ERBB2—urinary bladder cancer	6.87e-06	0.000106	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—EP300—urinary bladder cancer	6.86e-06	0.000105	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—GPX1—urinary bladder cancer	6.81e-06	0.000105	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—TYMS—urinary bladder cancer	6.8e-06	0.000105	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—NCOR1—urinary bladder cancer	6.72e-06	0.000103	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—GSTM1—urinary bladder cancer	6.72e-06	0.000103	CbGpPWpGaD
Dinoprostone—ABCC4—Hemostasis—HRAS—urinary bladder cancer	6.72e-06	0.000103	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GSTP1—urinary bladder cancer	6.71e-06	0.000103	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—ERCC2—urinary bladder cancer	6.68e-06	0.000103	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—SRC—urinary bladder cancer	6.67e-06	0.000103	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—KRAS—urinary bladder cancer	6.66e-06	0.000102	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CXCL8—urinary bladder cancer	6.65e-06	0.000102	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MYC—urinary bladder cancer	6.65e-06	0.000102	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling by GPCR—HRAS—urinary bladder cancer	6.61e-06	0.000102	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CXCL8—urinary bladder cancer	6.51e-06	0.0001	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CXCL8—urinary bladder cancer	6.51e-06	0.0001	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—EGFR—urinary bladder cancer	6.5e-06	0.0001	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling by GPCR—HRAS—urinary bladder cancer	6.47e-06	9.95e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—HRAS—urinary bladder cancer	6.47e-06	9.95e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—GPX1—urinary bladder cancer	6.44e-06	9.9e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—IL2—urinary bladder cancer	6.36e-06	9.78e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—ERCC2—urinary bladder cancer	6.32e-06	9.72e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—MTHFR—urinary bladder cancer	6.28e-06	9.66e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GSTP1—urinary bladder cancer	6.25e-06	9.61e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—TYMS—urinary bladder cancer	6.23e-06	9.58e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—IL2—urinary bladder cancer	6.22e-06	9.57e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—IL2—urinary bladder cancer	6.22e-06	9.57e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CCND1—urinary bladder cancer	6.2e-06	9.53e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—NCOR1—urinary bladder cancer	6.16e-06	9.47e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GSTM1—urinary bladder cancer	6.16e-06	9.47e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—KRAS—urinary bladder cancer	6.14e-06	9.45e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CCND1—urinary bladder cancer	6.07e-06	9.33e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CCND1—urinary bladder cancer	6.07e-06	9.33e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PTGS2—urinary bladder cancer	6.05e-06	9.3e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.03e-06	9.28e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—PTEN—urinary bladder cancer	6.02e-06	9.26e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MMP9—urinary bladder cancer	6.02e-06	9.25e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—TYMP—urinary bladder cancer	6.02e-06	9.25e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	6e-06	9.22e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PTEN—urinary bladder cancer	5.98e-06	9.2e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—MYC—urinary bladder cancer	5.98e-06	9.19e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—MTHFR—urinary bladder cancer	5.94e-06	9.14e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—TP53—urinary bladder cancer	5.92e-06	9.1e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—GPX1—urinary bladder cancer	5.9e-06	9.07e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MMP9—urinary bladder cancer	5.89e-06	9.06e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MMP9—urinary bladder cancer	5.89e-06	9.06e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.87e-06	9.02e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—CDKN1A—urinary bladder cancer	5.87e-06	9.02e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PTEN—urinary bladder cancer	5.86e-06	9e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PTEN—urinary bladder cancer	5.86e-06	9e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—EGFR—urinary bladder cancer	5.85e-06	8.99e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—TYMS—urinary bladder cancer	5.81e-06	8.93e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—ERCC2—urinary bladder cancer	5.79e-06	8.91e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.78e-06	8.88e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GSTM1—urinary bladder cancer	5.74e-06	8.83e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—NCOR1—urinary bladder cancer	5.74e-06	8.83e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Metabolism—EP300—urinary bladder cancer	5.74e-06	8.83e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—EP300—urinary bladder cancer	5.71e-06	8.77e-05	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—HRAS—urinary bladder cancer	5.66e-06	8.7e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	5.64e-06	8.66e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—EP300—urinary bladder cancer	5.58e-06	8.59e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—EP300—urinary bladder cancer	5.58e-06	8.59e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—SRC—urinary bladder cancer	5.55e-06	8.53e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—KRAS—urinary bladder cancer	5.52e-06	8.49e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—GPX1—urinary bladder cancer	5.5e-06	8.46e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—TP53—urinary bladder cancer	5.46e-06	8.4e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—MTHFR—urinary bladder cancer	5.45e-06	8.37e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.44e-06	8.37e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—SRC—urinary bladder cancer	5.43e-06	8.35e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—SRC—urinary bladder cancer	5.43e-06	8.35e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	5.41e-06	8.32e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—ERCC2—urinary bladder cancer	5.4e-06	8.3e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—PTEN—urinary bladder cancer	5.27e-06	8.11e-05	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—HRAS—urinary bladder cancer	5.22e-06	8.03e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PPARG—urinary bladder cancer	5.09e-06	7.83e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	5.08e-06	7.8e-05	CbGpPWpGaD
Dinoprostone—CYP11A1—Metabolism—EP300—urinary bladder cancer	5.03e-06	7.73e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MYC—urinary bladder cancer	4.97e-06	7.64e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—CREBBP—urinary bladder cancer	4.89e-06	7.52e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MYC—urinary bladder cancer	4.87e-06	7.48e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MYC—urinary bladder cancer	4.87e-06	7.48e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—EGFR—urinary bladder cancer	4.86e-06	7.48e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PPARG—urinary bladder cancer	4.82e-06	7.41e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—EGFR—urinary bladder cancer	4.76e-06	7.32e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—EGFR—urinary bladder cancer	4.76e-06	7.32e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.7e-06	7.22e-05	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—HRAS—urinary bladder cancer	4.69e-06	7.22e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—CREBBP—urinary bladder cancer	4.63e-06	7.12e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—KRAS—urinary bladder cancer	4.59e-06	7.06e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—KRAS—urinary bladder cancer	4.5e-06	6.91e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—KRAS—urinary bladder cancer	4.5e-06	6.91e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	4.43e-06	6.82e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PPARG—urinary bladder cancer	4.42e-06	6.79e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.35e-06	6.69e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.35e-06	6.69e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.32e-06	6.65e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	4.24e-06	6.52e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.22e-06	6.49e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.15e-06	6.39e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PPARG—urinary bladder cancer	4.12e-06	6.33e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—TP53—urinary bladder cancer	4.08e-06	6.28e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PTGS2—urinary bladder cancer	4.01e-06	6.16e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—TP53—urinary bladder cancer	4e-06	6.15e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—TP53—urinary bladder cancer	4e-06	6.15e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	3.95e-06	6.08e-05	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—HRAS—urinary bladder cancer	3.9e-06	6e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	3.87e-06	5.94e-05	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—HRAS—urinary bladder cancer	3.82e-06	5.88e-05	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—HRAS—urinary bladder cancer	3.82e-06	5.88e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PTGS2—urinary bladder cancer	3.79e-06	5.83e-05	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—EP300—urinary bladder cancer	3.69e-06	5.67e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.51e-06	5.39e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—PTEN—urinary bladder cancer	3.49e-06	5.37e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	3.47e-06	5.34e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.4e-06	5.23e-05	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—EP300—urinary bladder cancer	3.33e-06	5.12e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—PTEN—urinary bladder cancer	3.31e-06	5.08e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	3.24e-06	4.98e-05	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—EP300—urinary bladder cancer	3.15e-06	4.85e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—PTEN—urinary bladder cancer	3.03e-06	4.66e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.97e-06	4.56e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.92e-06	4.5e-05	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—EP300—urinary bladder cancer	2.89e-06	4.44e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.83e-06	4.35e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—PTEN—urinary bladder cancer	2.82e-06	4.34e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.72e-06	4.18e-05	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—EP300—urinary bladder cancer	2.69e-06	4.14e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.69e-06	4.13e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.69e-06	4.13e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.57e-06	3.96e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.53e-06	3.88e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.38e-06	3.65e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.93e-06	2.96e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.85e-06	2.84e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.52e-06	2.33e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.32e-06	2.03e-05	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.26e-06	1.94e-05	CbGpPWpGaD
